Almoosa Health Co. reported a net profit of SAR 51.1 million in Q1 2025, a more than three-fold increase from SAR 13.7 million in Q1 2024.
| Item | Q1 2024 | Q1 2025 | Change |
|---|---|---|---|
| Revenues | 277.16 | 322.98 | 16.5 % |
| Gross Income | 78.54 | 98.79 | 25.8 % |
| Operating Income | 30.64 | 48.06 | 56.8 % |
| Net Income | 13.73 | 51.13 | 272.5 % |
| Average Shares | 35.00 | 44.30 | 26.6 % |
| Earnings Per Share before unusual items (Riyal) | 0.39 | 1.09 | 178.9 % |
| EPS (Riyal) | 0.39 | 1.15 | 194.3 % |
| Item | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Revenues | 332.11 | 322.98 | (2.7 %) |
| Gross Income | 119.95 | 98.79 | (17.6 %) |
| Operating Income | 69.69 | 48.06 | (31.0 %) |
| Net Income | 54.03 | 51.13 | (5.4 %) |
| Average Shares | 35.00 | 44.30 | 26.6 % |
| Earnings Per Share before unusual items (Riyal) | 1.54 | 1.09 | (29.1 %) |
| EPS (Riyal) | 1.54 | 1.15 | (25.2 %) |
Operational efficiency in managing costs contributed to this improvement, with lower financing costs due to a loan settlement in Q1.
Q1 revenue grew by 16.5% year-on-year (YoY) to SAR 323 million, driven by an increase in inpatient and outpatient volumes at Almoosa Specialist Hospital and expansion of specialty offerings.
Additionally, the significant increase in net income was primarily driven by revenue growth, which resulted from an increase in patients’ volume in addition to higher inpatient occupancy.
EBITDA grew by 38% in Q1 2025 to SAR 73.9 million, with margin expansion to 22.9% from 19.3% in Q1 2024.
On a sequential basis, net earnings dropped 5.4% from SAR 54.03 million in Q4 2024.
Total shareholders’ equity, no minority interest, stood at SAR 1.9 billion as of March 31, 2025, compared to SAR 642.8 million a year earlier.
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website

Comments Analysis: